Sanofi

Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

The pharmaceutical industry traditionally tests excipient compatibility by incubating binary mixtures of API and excipient at stress conditions and testing over time by HPLC. These tests take up to 3 months to complete, slowing the progress of formulation development. DSC/MDSC analysis is a better technique over HPLC as it is faster, can detect chemical and physical changes, and is more ecofriendly using less materials.

Sanofi plans to create a standalone company dedicated to making active pharmaceutical ingredients, components that are biologically active in a drug, and will decide whether to list the API business on Euronext Paris by 2022.

Overall, the prospects for the sector remain strong, linked to the expected growth in healthcare. There is a strong case for investment in particular segments, subject to appropriate valuation and due diligence. This report highlights some of the trends that should be in the minds of CEOs, CFOs and investors.

Lonza to Host Free Webinar on Integrated QC Processes and Data Integrity   Walkersville, MD, USA / Cologne, Germany, 16 October 2015 – Lonza has announced that it will host […]

Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand […]